Commentary: Thrombolysis in stroke: It works!

British Medical Journal

Volumn 324, Issue 7339, 2002, Pages 727-729

  Saver, Jeffrey L ^a   Kidwell, Chelsea S ^a   Starkman, Sidney ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PROUROKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DATA ANALYSIS; NOTE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE;

EID: 0037160932     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (18)

1. Tissue plasminogen activator for acute ischemic stroke
2. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification
3. ATLANTIS trial: Results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
4. Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience
5. Thrombolysis for acute ischaemic stroke
6. Number needed to treat (NNT): Estimation of a mesaure of clinical benefit
7. Thrombolysis
8. Myths regarding the NINDS rt-PA Stroke trial: Setting the record straight
9. Empiric evidence of publication bias affecting acute stroke clinical trials
10. Relationships between authors of clinical practice guidelines and the pharmaceutical industry
11. Judging words rather than authors
12. Beyond conflict of interest. Transparency is the key
13. IV t-PA intervendonal therapy for acute stroke patients: Negative position
14. Duesberg, HIV and AIDS
15. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
16. Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project
17. Extending tissue plasminogen activator use to community and rural stroke patients
18. Recommendations for the establishment of primary stroke centers. Brain attack coalition